NOMO3: A Potential Drug Target and Biomarker (G408050)

Target Name: NOMO3

NCBI ID: G408050

NOMO3

NOMO3: A Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers is a crucial step in the development of new pharmaceuticals. NOMO3, a protein expressed in various tissues and cells, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential implications of NOMO3 as a drug target and biomarker.

Potential Drug Target

NOMO3 is a protein that is expressed in various tissues and cells, including the brain, muscle, heart, and gastrointestinal tract. It is involved in various cellular processes, including cell signaling, cell division, and cell adhesion. NOMO3 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of NOMO3 is its role in cell signaling. NOMO3 has been shown to play a role in the regulation of cell proliferation and differentiation. It has been shown to inhibit the activity of the oncogene transforming growth factor-尾 (TGF-β), which promotes cell proliferation. NOMO3 has also been shown to promote the inhibition of the transcription factor, p53, which protects against cell proliferation and has been implicated in the regulation of apoptosis.

In addition to its role in cell signaling, NOMO3 has also been shown to play a role in cell adhesion. NOMO3 is involved in the regulation of cell-cell adhesion and has been shown to promote the formation of tight junctions, which are a type of cell-cell adhesion.

Potential Biomarker

NOMO3 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NOMO3 has been shown to be abnormally expressed in several types of cancer, including breast, ovarian, and colorectal cancer. In addition, NOMO3 has also been shown to be abnormally expressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

NOMO3 has also been shown to be abnormally expressed in autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. In these disorders, NOMO3 has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune diseases.

Conclusion

In conclusion, NOMO3 is a protein that has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of NOMO3 in these diseases and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: NODAL Modulator 3

Functions: Component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes (PubMed:36261522, PubMed:32820719). The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions (PubMed:36261522)

The "NOMO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOMO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets